This result would partly contradict previous findings by Ignatov et al. (n = 5907) and Rossi et al. (n = 1150) studies, in which patients with HER2 IHC2 + /ISH-negative and early-stage BC had worse DFS than those with HER2 IHC 0 or 1 + 27,28. The gene discussed is ERBB2; the disease is breast cancer.